BioCentury
ARTICLE | Emerging Company Profile

Sera Prognostics: Predicting preemies

Sera predicting risk of preterm birth with blood-based protein assay

December 12, 2011 8:00 AM UTC

Sera Prognostics Inc. is developing a molecular test that it thinks will accurately predict more than 90% of women at risk for preterm birth, allowing earlier monitoring and preventive treatment. The company raised $19.3 million in a series A round in November that will take it to a launch in 2013.

The only methods currently available to predict preterm birth are history of a previous delivery before 37 weeks of gestation, and ultrasound measurement of the cervix around 20 weeks...